Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Indian Science
  4. Volume 2, Issue 1
  5. Article
Volume 2, Issue 1
  • ISSN: 2210-299X
  • E-ISSN: 2210-3007
file format pdf download PDF
side by side viewer icon HTML

Abstract

The COVID-19 emergency built pressure on US regulatory bodies to unlock the optional and short pathway of approval for urgently required pharmaceuticals to accomplish population demand for medicinal products within the shortest possible time to limit the suffering and deaths associated with insufficiency of medicinal products in need. During the pandemic, many medicinal products got emergency use authorization (EUA) according to the EUA guidelines provided by the US Food Drug Administration (USFDA). The requirement of abbreviated data submission for EUA attracted many pharmaceutical companies to launch their products as investigational drugs. Clinical data collected from the population is also permitted to get final approval. Comirnaty and Remdesivir got full approval using this regulatory tool. EUA does not ensure the existence of the medicinal product for an extended period. Whenever the emergency is over or the products are no longer needed, the USFDA revokes those according to their legislation. However, after Hydroxychloroquine phosphate and chloroquine sulfate were revoked due to failure to show efficacy, it grabbed the attention of many healthcare stakeholders in the country. It demanded more transparency in the approval pathway of present EUA guidelines. Two attributes, ., Current Good Manufacturing Practice exemption and expiry date extension, affect the quality of the medicinal products used during the pandemic. The most critical product distribution data, voluntary in EUA, remarkably endorse the black-marketing and shortage of specific COVID-19-related medicinal products in the pandemic situation. Amendments to the existing guidelines minimize the upcoming public health risk.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cis/10.2174/012210299X269869231128100928
2024-04-26
2025-04-18

  • From This Site

    /content/journals/cis/10.2174/012210299X269869231128100928
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. WHOWHO Director-General’s remarks at the media briefing on2019Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020
    [Google Scholar]
  2. GuidryJ.P.D. LaestadiusL.I. VragaE.K. MillerC.A. PerrinP.B. BurtonC.W. RyanM. FuemmelerB.F. CarlyleK.E. Willingness to get the COVID-19 vaccine with and without emergency use authorization.Am. J. Infect. Control202149213714210.1016/j.ajic.2020.11.01833227323
     [Google Scholar]
  3. WHO2023Available from: https://covid19.who.int/region/searo/country/in (Accessed on 2023 27 September).
  4. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University2022Available from: https://coronavirus.jhu.edu/map.html (Accessed on 2022 16th January).
  5. Van NormanG.A. Drugs, Devices, and the FDA: Part 2.JACC Basic Transl. Sci.20161427728710.1016/j.jacbts.2016.03.00930167516
     [Google Scholar]
  6. USFDAEbola Preparedness and Response Updates from FDA2021Available from: https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/ebola-preparedness-and-response-updates-fda(Accessed on 2021 10 December).
     [Google Scholar]
  7. USFDAZika Virus Response Updates from FDA2021Available from: https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/zika-virus-response-updates-fda(Accessed on 2021 24 December).
     [Google Scholar]
  8. USFDA. H7N9 Influenza EUA Information.2016Available from: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#H7N9(Accessed on 2021 25 December).
  9. USFDA. Emergency use authorization.2021Available from: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization(Accessed on 2021 12 November).
  10. Special Approval for Emergency on First COVID-19 Vaccine in Japan.Available from: https://www.pmda.go.jp/english/about-pmda/0003.pdf(Accessed on 2021 10 November).
  11. Conditional marketing authorisationAvailable from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/conditional-marketing-authorisation(Accessed on 2021 10 November).
     [Google Scholar]
  12. CDSCO. Guidance for approval Covid-19 vaccine in India for restricted use in emergency situation which are already approved for restricted use by USFDA, UK MHRA, EMA, PMDA Japan and which are listed in WHO EULAvailable from: https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/notice15april21.pdf(Accessed on 2023 27 September).
  13. FletcherE.P. MadabushiR. SahajwallaC.G. LeskoL.J. HuangS-M. The role of the FDA in guiding drug development. Atkinson’s Principles of Clinical Pharmacology.Elsevier202268169010.1016/B978‑0‑12‑819869‑8.00024‑0
     [Google Scholar]
  14. USFDA. fast track, breakthrough therapy, accelerated approval, priority review.Available from: https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review (Accessed on 2021 27 December).
  15. USFDA. FDA takes significant step in coronavirus response efforts, issues emergency use authorization for the first 2019 novel coronavirus diagnostic.Available from: https://www.fda.gov/news-events/press-announcements/fda-takes-significant-step-coronavirus-response-efforts-issues-emergency-use-authorization-first (Accessed on 2021 5 December).
  16. USFDA. Coronavirus (COVID-19) Update: FDA authorizes first oral antiviral for treatment of COVID-19.Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19 (Accessed 2021 31 December).
  17. HaqueA. PantA.B. Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy.J. Autoimmun.202212710279210.1016/j.jaut.2021.10279234995958
     [Google Scholar]
  18. NightingaleS.L. PrasherJ.M. SimonsonS. Emergency use authorization (EUA) to enable use of needed products in civilian and military emergencies.United States.2007
     [Google Scholar]
  19. USFDA. Emergency use authorization--archived information.Available from: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization-archived-information (Accessed on 2021 16 November).
  20. USFDA. Pandemic and all-hazards preparedness reauthorization act of 2013 (PAHPRA) medical countermeasure (MCM) authorities.Available from: https://www.fda.gov/media/87718/download (Accessed on 2021 1 October).
  21. ChenP.L. LeeN.Y. CiaC.T. KoW.C. HsuehP.R. A review of treatment of coronavirus disease 2019 (COVID-19): Therapeutic repurposing and unmet clinical needs.Front. Pharmacol.20201158495610.3389/fphar.2020.58495633364959
     [Google Scholar]
  22. USFDA. emergency use authorization of medical products and related authorities.Available from: https://www.fda.gov/media/97321/download (Accessed on 2021 23 December).
  23. USFDA. fact sheet for healthcare providers emergency use authorization (eua) of veklury® (remdesivir) for hospitalized pediatric patients weighing 3.5 kg to less than 40 kg or hospitalized pediatric patients less than 12 years of age weighing at least 3.5 kg.Available from: https://www.fda.gov/media/137566/download (Accessed on 2022 2 January).
  24. USFDA. Janssen COVID-19 vaccine EUA letter of authorization.Available from: https://www.fda.gov/media/146303/download (Accessed on 2021 11 December).
  25. USFDA. biothrax® (Anthrax Vaccine Adsorbed) emergent biosolutions.Available from: https://www.fda.gov/media/71954/download (Accessed on 2021 6 December).
  26. USFDA. Letter revoking EUA for chloroquine phosphate and hydroxychloroquine sulfate.Available from: https://www.fda.gov/media/138945/download (Accessed on 2021 12 December).
  27. USFDA. Pfizer-BioNTech COVID-19 Vaccine EUA LOA reissued.Available from: https://www.fda.gov/media/150386/download (Accessed on 2021 24 November).
  28. USFDA. Facts about the current good manufacturing practices (CGMPs) 2021.Available from: https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmps (Accessed on 2022 1 January).
  29. USFDA. Gilead issues a voluntary nationwide recall of two lots of Veklury® (Remdesivir) Due to presence of glass particulates.Available from: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/gilead-issues-voluntary-nationwide-recall-two-lots-vekluryr-remdesivir-due-presence-glass (Accessed on 2021 27 December).
  30. USFDA. FDA’s approval of Veklury (remdesivir) for the treatment of covid-19—the science of safety and effectiveness.Available from: https://www.fda.gov/drugs/news-events-human-drugs/fdas-approval-veklury-remdesivir-treatment-covid-19-science-safety-and-effectiveness (Accessed on 2021 25 December).
  31. UDFDA. expiration dating extension.Available from: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/expiration-dating-extension (Accessed on 2022 4 January).
  32. USFDA. expiration dating extension 2021.Available from: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/expiration-dating-extension (Accessed on 2021 28 December).
  33. USFDA. Letter of authorization - chloroquine phosphate and hydroxychloroquine sulfate.Available from: https://www.fda.gov/media/136534/download (Accessed on 2021 8 November).
  34. SombergJ. Science, politics and hydroxychloroquine.Cardiol. Res.202011526726810.14740/cr114032849959
     [Google Scholar]
  35. USFDA. Umbrella EUA for Non-NIOSH-Approved disposable filtering facepiece - letter of revocation.2021Available from: https://www.fda.gov/media/150461/download (Accessed on 2021 12 November).
  36. USFDA. gravity diagnostics COVID-19 assay - revocation letter.Available from: https://www.fda.gov/media/151030/download (Accessed on 2021 17 November).
  37. USFDA. Revocation of EUAA200179.Available from: https://www.fda.gov/media/139109/download (Accessed on 2021 1 December).
  38. USFDA. Serology umbrella revocation letter.Available from: https://www.fda.gov/media/140351/download (Accessed on 2021 2 December).
  39. USFDA. revocation of EUA200349.Available from: https://www.fda.gov/media/140908/download (Accessed on 2021 4 December).
  40. USFDA. Emergency Use Authorization (EUA) issued May 1, 2020, for emergency use of protective barrier enclosures.Available from: https://www.fda.gov/media/141415/download (Accessed on 2021 7 December).
  41. USFDA. Umbrella of infusion pumps and infusion pump accessories - letter of revocation.Available from: https://www.fda.gov/media/142374/download (Accessed on 2021 11 December).
  42. USFDA. Nova2200 EUA revocation letter.Available from: https://www.fda.gov/media/145896/download (Accessed on 2021 26 December).
  43. USFDA. revocation BiofireDx RP.Available from: https://www.fda.gov/media/146766/download (Accessed on 2021 1 November).
  44. USFDA. Revocation letter bamlanivimab.Available from: https://www.fda.gov/media/147629/download (Accessed on 2021 2 November).
  45. USFDA. Revocation of EUA200210.Available from: https://www.fda.gov/media/148132/download (Accessed on 2021 24 December).
  46. USFDA. STERIS sterilization systems for decontamination of n95 respirators - letter of revocation .Available from: https://www.fda.gov/media/150480/download (Accessed on 2021 3 November).
  47. USFDA. umbrella eua for imported, non-niosh-approved disposable filtering facepiece respirators (FFRs) - letter of revocation.Available from: https://www.fda.gov/media/150462/download (Accessed on 2021 7 November).
  48. USFDA. Curative SARS-Cov-2 assay - letter of revocation.Available from: https://www.fda.gov/media/150773/download (Accessed on 2021 13 November).
  49. USFDA. EUA-matmacorp-2sf -revocation-letter.Available from: https://www.fda.gov/media/151349/download (Accessed on 2021 19 November).
  50. USFDA. Guardant-19 - revocation letter.Available from: https://www.fda.gov/media/151378/download (Accessed on 2021 20 November).
  51. USFDA. EUA LifeThermo COVMS2COM revocation letter.Available from: https://www.fda.gov/media/152493/download (Accessed on 2021 21 November).
  52. USFDA. BioGX SARS-CoV-2 reagents for bd MAX system - revocation letter.Available from: https://www.fda.gov/media/154720/download (Accessed on 2022 3 January).
  53. USFDA. Akron Children’s Hospital SARS-CoV-2 Assay- revocation letter.Available from: https://www.fda.gov/media/154721/download (Accessed on 2022 5 January).
  54. USFDA. BMC-CReM COVID-19 test - revocation letter.Available from: https://www.fda.gov/media/154723/download (Accessed on 2022 15 January).
  55. USFDA. qSARS-CoV-2 IgG/IgM rapid test - revocation letter.Available from: https://www.fda.gov/media/154801/download (Accessed on 2022 17 January).
  56. USFDA. SARS-COV-2 R-GENE - letter of revocation.Available from: https://www.fda.gov/media/154977/download (Accessed on 2022 20 January).
  57. USFDA. ADVIA Centaur SARS-CoV-2 IgG (COV2G) - letter of revocation.Available from: https://www.fda.gov/media/154975/download (Accessed on 2022 24 January).
  58. USFDA. Atellica IM SARS-CoV-2 IgG (COV2G) - letter of revocation.Available from: https://www.fda.gov/media/154976/download (Accessed on 2022 23 January).
  59. USFDA. Xpert Omni SARS-CoV-2 - revocation letter.Available from: https://www.fda.gov/media/155259/download (Accessed on 2022 25 January).
  60. USFDA. BioPlex 2200 SARS-CoV-2 IgG - letter of revocation.Available from: https://www.fda.gov/media/155494/download (Accessed on 2022 26 January).
  61. USFDA. MosaiQ COVID-19 antibody magazine - letter of revocation.Available from: https://www.fda.gov/media/155493/download (Accessed on 2022 26 January).
  62. Services USDoHaH. determination that a public health emergency exists.Available from: https://www.phe.gov/emergency/news/healthactions/phe/Pages/2019-nCoV.aspx (Accessed on 2021 21 November).
  63. USFDA. Moderna COVID-19 vaccine eua letter of authorization.Available from: https://www.fda.gov/media/144636/download (Accessed on 2021 5 December).
  64. BeigelJ.H. TomashekK.M. DoddL.E. MehtaA.K. ZingmanB.S. KalilA.C. HohmannE. ChuH.Y. LuetkemeyerA. KlineS. Lopez de CastillaD. FinbergR.W. DierbergK. TapsonV. HsiehL. PattersonT.F. ParedesR. SweeneyD.A. ShortW.R. TouloumiG. LyeD.C. OhmagariN. OhM. Ruiz-PalaciosG.M. BenfieldT. FätkenheuerG. KortepeterM.G. AtmarR.L. CreechC.B. LundgrenJ. BabikerA.G. PettS. NeatonJ.D. BurgessT.H. BonnettT. GreenM. MakowskiM. OsinusiA. NayakS. LaneH.C. ACTT-1 Study Group Members Remdesivir for the treatment of covid-19–final report.N. Engl. J. Med.2020383191813182610.1056/NEJMoa200776432445440
     [Google Scholar]
  65. USFDA. fact sheet for healthcare providers: emergency use authorization for paxlovidtm 2021.Available from: https://www.fda.gov/media/155050/download (Accessed on 2022 18 January).
  66. USFDA. molnupiravir loa.Available from: https://www.fda.gov/media/155053/download (Accessed on 2022 18 January).
  67. USFDA. fact sheet for healthcare providers emergency use authorization (eua) of baricitinib.Available from: https://www.fda.gov/media/143823/download (Accessed on 2021 26 December).
  68. USFDA. FACT sheet for health care providers emergency use authorization (eua) of regen-cov® (casirivimab and imdevimab).Available from: https://www.fda.gov/media/145611/download (Accessed on 2021 29 December).
  69. USFDA. Bamlanivimab and etesevimab eua letter of authorization.Available from: https://www.fda.gov/media/145801/download (Accessed on 2021 27 December).
  70. USFDA. FACT sheet for health care providers emergency use authorization (eua) of bamlanivimab and etesevimab.Available from: https://www.fda.gov/media/145802/download (Accessed on 2021 27 December).
  71. USFDA. GSK sotrovimab letter of authorization.Available from: https://www.fda.gov/media/149532/download (Accessed on 2021 25 December).
  72. USFDA. FACT sheet for healthcare providers emergency use authorization (eua) of sotrovimab.Available from: https://www.fda.gov/media/149534/download (Accessed on 2021 4 December).
  73. USFDA. Genentech tocilizumab Letter of Authority.Available from: https://www.fda.gov/media/150319/download (Accessed on 2021 13 December).
  74. USFDA. FACT sheet for healthcare providers: emergency use authorization for actemra® (tocilizumab).Available from: https://www.fda.gov/media/150321/download (Accessed on 2021 28 December).
  75. IsonM.G. WolfeC. BoucherH.W. Emergency use authorization of remdesivir: The need for a transparent distribution process.JAMA2020323232365236610.1001/jama.2020.886332407438
     [Google Scholar]
/content/journals/cis/10.2174/012210299X269869231128100928
Loading
Exploration & Outcomes of Emergency Use Authorization during the COVID-19 Pandemic in the United States
Curr. Indian Sci. 2, e2210299X269869 (2024); https://doi.org/10.2174/012210299X269869231128100928
/content/journals/cis/10.2174/012210299X269869231128100928
/content/journals/cis/10.2174/012210299X269869231128100928
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Review Article
Keyword(s): COVID-19 pandemic; Current good manufacturing practice exemption; Emergency use authorization; Emergency use authorization revoke; Expiry date extension; WHO

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test